Overview

Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis

Status:
Unknown status

Trial end date:
2017-03-01

Target enrollment:

Participant gender:

Summary

To assess efficacy (SVR rate) of MK5172 / MK8742 for 12 weeks without RBV in G1b patients with compensated cirrhosis (Child-Pugh A5 to A6) previously failing first gen. PI or non responders to PR.

Phase:

Phase 3

Details

Lead Sponsor:

Istituto Clinico Humanitas

Collaborator:

CD Pharma Group S.r.l.

Treatments:

Grazoprevir
Ribavirin